SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-012405
Filing Date
2017-11-20
Accepted
2017-11-20 17:16:47
Documents
61
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0917_dandritbiotech.htm 10-Q 357098
2 CERTIFICATION f10q0917ex31-1_dandritbio.htm EX-31.1 8241
3 CERTIFICATION f10q0917ex31-2_dandritbio.htm EX-31.2 8263
4 CERTIFICATION f10q0917ex32-1_dandritbio.htm EX-32.1 3944
5 CERTIFICATION f10q0917ex32-2_dandritbio.htm EX-32.2 3939
  Complete submission text file 0001213900-17-012405.txt   3113217

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE ddrt-20170930.xml EX-101.INS 449628
7 XBRL SCHEMA FILE ddrt-20170930.xsd EX-101.SCH 44557
8 XBRL CALCULATION FILE ddrt-20170930_cal.xml EX-101.CAL 47243
9 XBRL DEFINITION FILE ddrt-20170930_def.xml EX-101.DEF 134709
10 XBRL LABEL FILE ddrt-20170930_lab.xml EX-101.LAB 407222
11 XBRL PRESENTATION FILE ddrt-20170930_pre.xml EX-101.PRE 264463
Mailing Address STUMPEDYSSEVEJ 17, 2970 H?RSHOLM G7
Business Address STUMPEDYSSEVEJ 17, 2970 H?RSHOLM G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

IRS No.: 452259340 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54478 | Film No.: 171214613
SIC: 2834 Pharmaceutical Preparations